SCHEMBL16899807

SCHEMBL16899807

CC1(C)OB(c2cnc(-c3cccc(-c4cnn(CCN5CCOCC5)c4)c3)nc2)OC1(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IRAK1 P51617 7/20 0.49
▸ IRAK4 Q9NWZ3 6/20 0.49
▸ MAP4K4 O95819 1/20 0.41
▸ NR5A2 O00482 1/20 0.41
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ CYP11B2 P19099 1/20 0.39
▸ IKBKE Q14164 1/20 0.39
▸ TBK1 Q9UHD2 1/20 0.39
▸ IGF1R P08069 1/20 0.39
▸ PIK3CD O00329 1/20 0.38
▸ PIK3R2 O00459 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ PIK3R5 Q8WYR1 1/20 0.38
▸ PIK3R3 Q92569 1/20 0.38
▸ ABL1 P00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16899802 0.89 JAK2 (0.42) IRAK1IRAK4MAP4K4NR5A2JAK2
SCHEMBL15431236 0.83 IRAK1 (0.62) IRAK1IRAK4NR5A2CYP11B2
SCHEMBL15416425 0.82 IRAK1 (0.49) IRAK1IRAK4
SCHEMBL16899776 0.81 IRAK1 (0.52) IRAK1IRAK4MAP4K4NR5A2JAK2
SCHEMBL20368 0.79 FFAR1 (0.53) MAP4K4JAK2JAK1TYK2JAK3
SCHEMBL18082578 0.76 IRAK4 (0.47) IRAK1IRAK4MAP4K4NR5A2JAK2
SCHEMBL10215021 0.75 LPL (0.43) MAP4K4JAK2JAK1TYK2JAK3
SCHEMBL1581528 0.75 IRAK4 (0.48) IRAK1IRAK4MAP4K4CYP11B2IKBKE
SCHEMBL12547490 0.75 NCF1 (0.46) IRAK1IRAK4MAP4K4CYP11B2IKBKE
SCHEMBL15431602 0.74 IRAK1 (0.51) IRAK1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10314841-B2 Substituted pyrazoles as IRAK inhibitors MERCK PATENT GMBH (DE) 2019-06-11 — — US disclosed
US-10314841-B2 Substituted pyrazoles as IRAK inhibitors MERCK PATENT GMBH (DE) 2019-06-11 — — US disclosed
US-20180169094-A1 PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS MERCK PATENT GMBH (DE) 2018-06-21 — — US disclosed
US-20180169094-A1 PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS MERCK PATENT GMBH (DE) 2018-06-21 — — US disclosed
US-20180169094-A1 PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS MERCK PATENT GMBH (DE) 2018-06-21 — — US disclosed
EP-3092225-A1 PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS Merck Patent GmbH (DE) 2016-11-16 — — EP disclosed
WO-2015106058-A1 PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS MERCK PATENT GMBH (DE) 2015-07-16 — — WO disclosed
WO-2015106058-A1 PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS MERCK PATENT GMBH (DE) 2015-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180169094-A1 PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS IRAK2, IRAK3, IRAK1 IRAK1 3/4885IRAK4 4/4885MAP4K4 316/4885
US-10314841-B2 Substituted pyrazoles as IRAK inhibitors IRAK2, IRAK3, IRAK1 IRAK1 3/4885IRAK4 4/4885MAP4K4 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback